Sarepta has been hit with another patent infringement lawsuit, this time from Sanofi and its subsidiary Genzyme alleging that the biotech used protected technology related to AAV vectors.
Tag Archive for: AAV vectors
Even though there has been much innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought to the forefront the need for even more advancement in the field. This article reviews some of the innovations that are occurring to address these issues.